Status:
UNKNOWN
Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial).
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Acute on Chronic Liver Failure
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The AIM of the study is to study the efficacy of intravenous albumin and standard medical treatment as compared to standard medical treatment alone in ameliorating/preventing SIRS and improving surviv...
Eligibility Criteria
Inclusion
- Age \>18 years to 65 years
- ACLF patients
Exclusion
- Patients who have already received albumin in last 1 week
- Patients who require albumin like PICD (Paracentesis-Induced Circulatory Dysfunction)
- ,SBP (Spontaneous bacterial peritonitis),LVP(large volume paracentesis),HRS(hepatorenal syndrome)
- Not given consent
- Significant cardiopulmonary or structural heart disease/ CKD(chronic kidney diseses) /volume overload /upper GI bleed.
- Pregnant/ HIV / HCC \>2cm size
- Alcoholic hepatitis eligible for steroids
- Previous known allergic/adverse reaction to albumin
- Any clinical condition which the investigator considers would make the patient unsuitable for the trial
- Patients who will receive palliative treatment only during their hospital admission
Key Trial Info
Start Date :
September 10 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03754400
Start Date
September 10 2018
End Date
July 30 2020
Last Update
April 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India, 110070